logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5662.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5662.produseast1
Showing 1 - 20 of 34 Items
Showing 1 - 20 of 34 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Research

Oral regimens for rifampin-resistant, fluoroquinolone-susceptible tuberculosis

Guglielmetti L, Khan U, Velásquez GE, Gouillou M, Abubakirov A,  et al.
2025-01-29 • New England Journal of Medicine
2025-01-29 • New England Journal of Medicine

BACKGROUND

For decades, poor treatment options and low-quality evidence plagued care for patients with rifampin-resistant tuberculosis. The advent of new drugs ...

Conference Material
|
Slide Presentation
Conference Material
|
Video

Improving treatment of multidrug-resistant tuberculosis: Results of the endTB randomised clinical trial

Guglielmetti L
2024-05-16 • MSF Scientific Day International 2024
2024-05-16 • MSF Scientific Day International 2024
Conference Material
|
Abstract
Journal Article
|
Review
Journal Article
|
Research
Conference Material
|
Slide Presentation
Technical Report
|
Evidence Brief
Journal Article
|
Research
Journal Article
|
Letter

Revised definitions of multidrug-resistant tuberculosis treatment outcomes: closer to the reality?

Bastard M, Bonnet MMB, du Cros PAK, Khamraev AK, 
Journal Article
|
Research
Journal Article
|
Short Report
Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Commentary
Journal Article
|
Research
Journal Article
|
Protocol
Journal Article
|
Research
Research & Publication Resources
|
Research Protocol
Journal Article
|
Research

Improving treatment of multidrug-resistant tuberculosis: Results of the endTB randomised clinical trial

Guglielmetti L, Khan U, Velasquez GE, Gouillou M, Lachenal N,  et al.
2024-05-16 • MSF Scientific Day International 2024
2024-05-16 • MSF Scientific Day International 2024

Improving treatment of multidrug-resistant tuberculosis: Results of the endTB randomised clinical trial

Guglielmetti L, Khan U, Velasquez GE, Gouillou M, Lachenal N,  et al.
2024-05-16 • MSF Scientific Day International 2024
2024-05-16 • MSF Scientific Day International 2024
INTRODUCTION
Tuberculosis (TB) is a major public health challenge encountered across many Médecins Sans Frontières (MSF) fields. Management of drug-resistant TB is an operational pri...

The safety and tolerability of linezolid in novel short-course regimens containing bedaquiline, pretomanid, and linezolid to treat rifampicin-resistant tuberculosis: An individual patient data meta-analysis

Hasan T, Medcalf E, Nyang'wa BT, Egizi E, Berry C,  et al.
2024-03-20 • Clinical Infectious Diseases
2024-03-20 • Clinical Infectious Diseases
BACKGROUND
Effectiveness, safety, tolerability, and adherence are critical considerations in shifting to shorter tuberculosis (TB) regimens. Novel 6-month oral regimens that include ...

Nine-month, all-oral regimens for rifampin-resistant tuberculosis

Guglielmetti L, Khan U, Velasquez GE, Gouillou M, Abubakirov A,  et al.
2024-01-29 • medRxiv
2024-01-29 • medRxiv

BACKGROUND

Aft...

endTB Clinical Trial: Design, efficacy, safety & linezolid dose-reduction randomization results

endTB Study Group
2023-11-15 • The Union World Conference on Lung Health 2023
2023-11-15 • The Union World Conference on Lung Health 2023

High-quality evidence on new, all-oral, shortened MDR-TB regimens

endTB Study Group
2023-11-15
2023-11-15
Each year there are approximately 500,000 new cases of multidrug-resistant tuberculosis (MDR-TB) worldwide, but only a tiny fraction is successfully treated. The endTB trial, led by Méde...

Concordance of three approaches for operationalizing outcome definitions for multidrug-resistant TB

Zeng C, Mitnick CD, Hewison CCH, Bastard M, Khan PY,  et al.
2023-01-01 • International Journal of Tuberculosis and Lung Disease
2023-01-01 • International Journal of Tuberculosis and Lung Disease
BACKGROUND
The WHO provides standardized outcome definitions for rifampicin-resistant (RR) and multidrug-resistant (MDR) TB. However, operationalizing these definitions can be challe...
Hayrapetyan A, 
et al.
2015-02-01 • American Journal of Respiratory and Critical Care Medicine
2015-02-01 • American Journal of Respiratory and Critical Care Medicine

Does One Size Fit All? Drug Resistance and Standard Treatments: Results of Six Tuberculosis Programmes in Former Soviet Countries

Bonnet MMB, Sizaire V, Kebede YYK, Janin A, Doshetov D,  et al.
2005-10-01 • International Journal of Tuberculosis and Lung Disease
2005-10-01 • International Journal of Tuberculosis and Lung Disease
SETTING: After the collapse of the Soviet Union, countries in the region faced a dramatic increase in tuberculosis cases and the emergence of drug resistance. OBJECTIVE: To discuss the r...

Culture conversion at six months in patients receiving delamanid-containing regimens for the treatment of multidrug-resistant tuberculosis

Seung KJ, Khan PY, Franke MF, Ahmed SM, Aiylchiev S,  et al.
2019-11-02 • Clinical Infectious Diseases
2019-11-02 • Clinical Infectious Diseases
Delamanid should be effective against highly resistant strains of Mycobacterium tuberculosis, but uptake has been slow globally. In the endTB (expand new drug markets for TB) Observation...

Risk factors associated with loss to follow-up among multidrug-resistant tuberculosis patients in Georgia

Kuchukhidze G, Kumar AMV, de Colombani P, Khogali MA, Nanava U,  et al.
2014-10-21 • Public Health Action
2014-10-21 • Public Health Action
SETTING
Georgia, a country with a high-burden of multi-drug-resistant tuberculosis (MDR-TB).

OBJECTIVE
To determine the proportion of loss to follow-up (LFU) among MDR-T...

Effects of Treatment Interruption Patterns on Treatment Success Among Patients With Multidrug-Resistant Tuberculosis in Armenia and Abkhazia

Bastard M, Sanchez-Padilla E, Hewison CCH, Hayrapetyan A, Khurkhumal S,  et al.
2014-10-13 • Journal of Infectious Diseases
2014-10-13 • Journal of Infectious Diseases
The success of the current treatment regimen for multidrug-resistant tuberculosis (MDR-TB) is poor partly due to a high defaulter rate. Many studies explored predictors of poor outcomes,...

The 'frozen state' of drug-resistant tuberculosis: notes from the field in Abkhazia

Majumdar S, O'Brien DP, Hurtado N, Hewison CCH, du Cros PAK
2011-12-08 • Internal Medicine Journal
2011-12-08 • Internal Medicine Journal

Outcomes of HIV-infected versus HIV-non-infected patients treated for drug-resistance tuberculosis: Multicenter cohort study

Bastard M, Sanchez-Padilla E, du Cros PAK, Khamraev AK, Parpieva N,  et al.
2018-03-08 • PLOS One
2018-03-08 • PLOS One
The emergence of resistance to anti-tuberculosis (DR-TB) drugs and the HIV epidemic represent a serious threat for reducing the global burden of TB. Although data on HIV-negative DR-TB t...

Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial

Guglielmetti L, Ardizzoni E, Atger M, Baudin E, Berikova E,  et al.
2021-09-25 • Trials
2021-09-25 • Trials
BACKGROUND
Treatment of multidrug- and rifampin-resistant tuberculosis (MDR/RR-TB) is expensive, labour-intensive, and associated with substantial adverse events and poor outcomes. W...

Determining the lower limit of detection required for HCV viral load assay for test of cure following direct-acting antiviral based treatment regimens: evidence from a global dataset

Morgan JR, Marsh E, Savinkina A, Shilton S, Shadaker S,  et al.
2022-03-12 • Journal of Viral Hepatitis
2022-03-12 • Journal of Viral Hepatitis
Achieving global elimination of hepatitis C virus requires a substantial scale-up of testing. Point-of-care HCV viral load assays are available as an alternative to laboratory-based assa...

The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens

Khan UT, Huerga H, Khan AS, Mitnick CD, Hewison CCH,  et al.
2019-08-20 • BMC Infectious Diseases
2019-08-20 • BMC Infectious Diseases
BACKGROUND
At a time when programs were struggling to design effective regimens for the treatment of multidrug-resistant tuberculosis (MDR-TB), the marketing authorization of bedaqui...

Outcomes of Bedaquiline Treatment in Patients with Multidrug-Resistant Tuberculosis

Mbuagbaw L, Guglielmetti L, Hewison CCH, Bakare N, Bastard M,  et al.
2019-05-01 • Emerging Infectious Diseases
2019-05-01 • Emerging Infectious Diseases
Bedaquiline is recommended by the World Health Organization for the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB). We pooled data from 5 c...